Impact of HER-2 overexpression/amplification on the prognosis of gastric cancer patients undergoing resection: A single-center study of 1,036 patients

Oncologist

Volumn 16, Issue 12, 2011, Pages 1706-1713

  Hsu, Jun Te ^a   Chen, Tse Ching ^a   Tseng, Jeng Hwei ^a   Chiu, Cheng Tang ^a   Liu, Keng Hao ^a   Yeh, Chun Nan ^a   Hwang, Tsann Long ^a   Jan, Yi Yin ^a   Yeh, Ta Sen ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Fish; Gastric cancer; Her 2; Ihc; Prognosis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; DISEASE ASSOCIATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; STOMACH CANCER; TISSUE MICROARRAY;

AGED; COHORT STUDIES; FEMALE; GASTRECTOMY; GENE AMPLIFICATION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; PROGNOSIS; RECEPTOR, ERBB-2; STOMACH NEOPLASMS;

EID: 84855171710     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2011-0199     Document Type: Article

References (22)

1. Jemal A, Siegel R, Xu J et al. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Dikken JL, Jansen EP, Cats A et al. Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer. J Clin Oncol 2010;28:2430-2436.
3. Van Cutsem E, Moiseyenko VM, Tjulandin S et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: A report of the V325 Study Group. J Clin Oncol 2006;24:4991-4997.
4. Cunningham D, Starling N, Rao S et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008;358:36-46.
5. Gravalos C, Jimeno A. HER2 in gastric cancer: Anew prognostic factor and a novel therapeutic target. Ann Oncol 2008;19:1523-1529.
6. Moasser MM. The oncogene HER2: Its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 2007;26: 6469-6487.
7. Ross JS, Slodkowska EA, Symmans WF et al. The HER-2 receptor and breast cancer: Ten years of targeted anti-HER-2 therapy and personalized medicine. The Oncologist 2009;14:320-368.
8. Tanner M, Hollmén M, Junttila TT et al. Amplification of HER-2 in gastric carcinoma: Association with topoisomerase IIα gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 2005;16:273-278.
9. Bang YJ, Van Cutsem E, Feyereislova A et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 2010;376:687-697.
10. Barros-Silva JD, Leitão D, Afonso L et al. Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients. Br J Cancer 2009;100: 487-493.
11. Jørgensen JT. Targeted HER2 treatment in advanced gastric cancer. Oncology 2010;78:26-33.
12. Kim MA, Jung EJ, Lee HS et al. Evaluation of HER-2 gene status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization, and real-time quantitative polymerase chain reaction. Hum Pathol 2007;38:1386-1393.
13. Greence FL, Page DL, Fleming ID et al. American Joint Committee on Cancer. AJCC Cancer Staging Manual, Sixth Ed. New York: Springer, 2002:99-103.
14. Hofmann M, Stoss O, Shi D et al. Assessment of a HER2 scoring system for gastric cancer: Results from a validation study. Histopathology 2008; 52:797-805.
15. Begnami MD, Fukuda E, Fregnani JH et al. Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinoma: HER2 and HER3 are predictors of poor outcome. J Clin Oncol 2011;22:3030-3036.
16. Park DI, Yun JW, Park JH et al. Her2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci 2006;51:1371-1379.
17. Berx G, Becker KF, Höfler H et al. Mutations of the human E-cadherin (CDH1) gene. Hum Mutat 1998;12:226-237.
18. Wang SY, Yeh CN, Lee HL et al. Clinical impact of positive surgical margin status on gastric cancer patients undergoing gastrectomy. Ann Surg Oncol 2009;16:2738-2743.
19. Lee KE, Lee HJ, Kim Y.H. et al. Prognostic significance of p53, nm23, PCNA and cerbB-2 in gastric cancer. Jpn J Clin Oncol 2003;33:173-179.
20. Yu GZ, Chen Y, Wang JJ. Overexpression of Grb2/HER2 signaling in Chinese gastric cancer: Their relationship with clinicopathological parameters and prognostic significance. J Cancer Res Clin Oncol 2009;135:1331-1339.
21. Fujimoto-Ouchi K, Sekiguchi F, Yasuno H et al. Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models. Cancer Chemother Pharmacol 2007;59:795-805.
22. Kim SY, Kim HP, Kim YJ et al. Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin. Int J Oncol 2008;32:89-95.